TRIM38

Summary

TRIM38 (tripartite motif containing 38, HGNC:10059) is a protein-coding gene on chromosome 6p22.2, encoding E3 ubiquitin-protein ligase TRIM38 (O00635). E3 ubiquitin-protein and E3 SUMO-protein ligase that acts as a regulator of innate immunity.

This gene encodes a member of the tripartite motif (TRIM) family. The encoded protein contains a RING-type zinc finger, B box-type zinc finger and SPRY domain. The function of this protein has not been identified. A pseudogene of this gene is located on the long arm of chromosome 4.

Source: NCBI Gene 10475 — RefSeq curated summary.

At a glance

• GWAS associations: 19
• Clinical variants (ClinVar): 55 total
• MANE Select transcript: NM_006355

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10059
Approved symbol	TRIM38
Name	tripartite motif containing 38
Location	6p22.2
Locus type	gene with protein product
Status	Approved
Aliases	RORET
Ensembl gene	ENSG00000112343
Ensembl biotype	protein_coding
Entrez	10475

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 13 protein_coding

ENST00000357085, ENST00000859133, ENST00000859134, ENST00000859135, ENST00000859136, ENST00000859137, ENST00000859138, ENST00000859139, ENST00000859140, ENST00000859141, ENST00000934128, ENST00000961974, ENST00000961975

RefSeq mRNA: 1 — MANE Select: NM_006355 NM_006355

CCDS: CCDS4568

Canonical transcript exons

ENST00000357085 — 8 exons

Exon	Start	End
ENSE00000701524	25969325	25969420
ENSE00000701617	25971869	25972099
ENSE00000701675	25973054	25973076
ENSE00000701768	25973173	25973285
ENSE00000848412	25983164	25991231
ENSE00001186600	25966335	25966933
ENSE00002227650	25963049	25963282
ENSE00002260222	25962802	25962855

Expression profiles

Bgee: expression breadth ubiquitous, 285 present calls, max score 97.78.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.1226 / max 274.0880, expressed in 1754 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
66454	12.8685	1717
66455	3.3630	948
66453	1.8604	984
66456	0.0307	19

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cardia of stomach	UBERON:0001162	97.78	gold quality
renal medulla	UBERON:0000362	97.52	gold quality
pylorus	UBERON:0001166	97.22	gold quality
nipple	UBERON:0002030	96.84	gold quality
buccal mucosa cell	CL:0002336	96.63	gold quality
superior surface of tongue	UBERON:0007371	96.54	gold quality
ventral tegmental area	UBERON:0002691	96.19	gold quality
lateral globus pallidus	UBERON:0002476	96.16	gold quality
vena cava	UBERON:0004087	95.82	gold quality
trigeminal ganglion	UBERON:0001675	95.80	gold quality
inferior vagus X ganglion	UBERON:0005363	95.73	gold quality
subthalamic nucleus	UBERON:0001906	95.68	gold quality
pericardium	UBERON:0002407	95.64	gold quality
superior vestibular nucleus	UBERON:0007227	95.48	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	95.27	gold quality
pharyngeal mucosa	UBERON:0000355	95.02	gold quality
tongue	UBERON:0001723	95.00	gold quality
substantia nigra pars compacta	UBERON:0001965	94.86	gold quality
tendon of biceps brachii	UBERON:0008188	94.72	gold quality
substantia nigra pars reticulata	UBERON:0001966	94.57	gold quality
saphenous vein	UBERON:0007318	94.47	gold quality
body of tongue	UBERON:0011876	94.45	gold quality
dorsal root ganglion	UBERON:0000044	94.41	gold quality
lateral nuclear group of thalamus	UBERON:0002736	94.40	gold quality
trachea	UBERON:0003126	93.80	gold quality
dorsal plus ventral thalamus	UBERON:0001897	93.75	gold quality
pons	UBERON:0000988	93.59	gold quality
urethra	UBERON:0000057	93.52	gold quality
nasal cavity epithelium	UBERON:0005384	93.49	gold quality
corpus epididymis	UBERON:0004359	93.36	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	14.11

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

135 targeting TRIM38, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-7153-5P	99.94	68.89	1006
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-4697-3P	99.89	67.09	1123
HSA-MIR-302A-3P	99.89	71.23	1777
HSA-MIR-302B-3P	99.89	71.23	1777
HSA-MIR-302C-3P	99.89	71.20	1778
HSA-MIR-302D-3P	99.89	71.25	1777
HSA-MIR-6857-5P	99.87	65.32	985
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-373-3P	99.84	70.68	1668
HSA-MIR-520E-3P	99.84	70.55	1698

Literature-anchored findings (GeneRIF, showing 9)

• Enterovirus 71 infection induces degradation of TRIM38. (PMID:21306652)
• NF-kappaB is activated in response to TRIM38. (PMID:21789858)
• TRIM38 may act as a novel negative regulator for TLR3-mediated type I interferon signaling by targeting TRIF for degradation (PMID:23056470)
• Data suggest that mRNA/protein levels of NLRP6 are down-regulated in synovial tissues and synoviocytes of rheumatoid arthritis (RA) patients compared to osteoarthritis patients; NLRP6 provides docking site to facilitate interaction between TAB2/3 and TRIM38 in RA synoviocytes in response to TNFalpha. (NLRP6 = ; TAB2/3 = transforming growth factor-b-activated kinase 1-binding protein 2/3; TRIM38 = tripartite motif 38) (PMID:28295271)
• TRIM38 triggers the uniquitination and degradation of glucose transporter type 1 (GLUT1) to restrict tumor progression in bladder cancer. (PMID:34906161)
• The antiviral activity of tripartite motif protein 38 in hepatitis B virus replication and gene expression and its association with treatment responses during PEG-IFN-alpha antiviral therapy. (PMID:36623352)
• Tripartite motif 38 alleviates the pathological process of NAFLD-NASH by promoting TAB2 degradation. (PMID:37116711)
• TRIM38 suppresses migration, invasion, metastasis, and proliferation in non-small cell lung cancer (NSCLC) via regulating the AMPK/NF-kappaB/NLRP3 pathway. (PMID:37566200)
• Investigation into the role of the MITA-TRIM38 interaction in regulating pyroptosis and maintaining immune tolerance at the maternal-fetal interface. (PMID:38012139)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
mus_musculus	Trim38	ENSMUSG00000064140

Paralogs (80): MID2 (ENSG00000080561), TRIM9 (ENSG00000100505), MID1 (ENSG00000101871), MEFV (ENSG00000103313), TRIM35 (ENSG00000104228), TRIM14 (ENSG00000106785), TRIM37 (ENSG00000108395), TRIM2 (ENSG00000109654), TRIM3 (ENSG00000110171), TRIM62 (ENSG00000116525), TRIM67 (ENSG00000119283), TRIM32 (ENSG00000119401), BSPRY (ENSG00000119411), TRIM25 (ENSG00000121060), TRIM6 (ENSG00000121236), TRIM24 (ENSG00000122779), TRIM51 (ENSG00000124900), TRIM28 (ENSG00000130726), TRIM21 (ENSG00000132109), TRIM5 (ENSG00000132256), TRIM22 (ENSG00000132274), TRIM47 (ENSG00000132481), TRIM45 (ENSG00000134253), TRIM29 (ENSG00000137699), TRIM54 (ENSG00000138100), PML (ENSG00000140464), TRIM65 (ENSG00000141569), TRIM43B (ENSG00000144010), TRIM43 (ENSG00000144015), TRIM7 (ENSG00000146054), TRIM41 (ENSG00000146063), TRIM50 (ENSG00000146755), TRIM4 (ENSG00000146833), TRIM55 (ENSG00000147573), TRIM48 (ENSG00000150244), TRIM36 (ENSG00000152503), TRIM11 (ENSG00000154370), TRIM74 (ENSG00000155428), TRIM42 (ENSG00000155890), TRIM63 (ENSG00000158022)

Protein

Protein identifiers

E3 ubiquitin-protein ligase TRIM38 — O00635 (reviewed: O00635)

Alternative names: RING finger protein 15, Tripartite motif-containing protein 38, Zinc finger protein RoRet

All UniProt accessions (1): O00635

UniProt curated annotations — full annotation on UniProt →

Function. E3 ubiquitin-protein and E3 SUMO-protein ligase that acts as a regulator of innate immunity. Acts as a negative regulator of type I interferon IFN-beta production by catalyzing ‘Lys-48’-linked polyubiquitination of AZI2/NAP1, leading to its degradation. Mediates ‘Lys-48’-linked polyubiquitination and proteasomal degradation of the critical TLR adapter TICAM1, inhibiting TLR3-mediated type I interferon signaling. Acts as positive regulator of the cGAS-STING pathway by acting as a E3 SUMO-protein ligase: mediates sumoylation of CGAS and STING, preventing their degradation and thereby activating the innate immune response to DNA virus. Also acts as a negative regulator of NF-kappa-B signaling independently of its E3 protein ligase activity by promoting lysosome-dependent degradation of TAB2 and TAB3 adapters.

Subunit / interactions. Interacts (via B30.2/SPRY domain) with TAB2 and TAB3.

Subcellular location. Cytoplasm.

Tissue specificity. Ubiquitous.

Pathway. Protein modification; protein ubiquitination. Protein modification; protein sumoylation.

RefSeq proteins (1): NP_006346* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000315	Znf_B-box	Domain
IPR001841	Znf_RING	Domain
IPR001870	B30.2/SPRY	Domain
IPR003877	SPRY_dom	Domain
IPR003879	Butyrophylin_SPRY	Domain
IPR006574	PRY	Domain
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR017907	Znf_RING_CS	Conserved_site
IPR035790	SPRY/PRY_TRIM38	Domain
IPR043136	B30.2/SPRY_sf	Homologous_superfamily
IPR050143	TRIM/RBCC	Family

Pfam: PF00622, PF00643, PF13765, PF15227

UniProt features (12 total): binding site 4, sequence conflict 2, zinc finger region 2, chain 1, domain 1, modified residue 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O00635-F1	87.31	0.58

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (4): 93; 96; 115; 121

Post-translational modifications (1): 70

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-877300	Interferon gamma signaling

MSigDB gene sets: 214 (showing top): GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_DN, MULLIGHAN_NPM1_SIGNATURE_3_UP, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_REGULATION_OF_DEFENSE_RESPONSE_TO_VIRUS, GOZGIT_ESR1_TARGETS_DN, GOBP_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_VIRAL_GENOME_REPLICATION, GOBP_NEGATIVE_REGULATION_OF_RESPONSE_TO_BIOTIC_STIMULUS, GOBP_PEPTIDYL_LYSINE_MODIFICATION, GOBP_NEGATIVE_REGULATION_OF_DEFENSE_RESPONSE_TO_VIRUS, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_REGULATION_OF_BIOLOGICAL_PROCESS_INVOLVED_IN_SYMBIOTIC_INTERACTION, BLALOCK_ALZHEIMERS_DISEASE_UP, GOBP_CYTOKINE_PRODUCTION

GO Biological Process (16): regulation of gene expression (GO:0010468), protein sumoylation (GO:0016925), regulation of interferon-beta production (GO:0032648), positive regulation of canonical NF-kappaB signal transduction (GO:0043123), proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161), positive regulation of viral genome replication (GO:0045070), innate immune response (GO:0045087), regulation of viral entry into host cell (GO:0046596), positive regulation of viral entry into host cell (GO:0046598), negative regulation of defense response to virus (GO:0050687), protein K48-linked ubiquitination (GO:0070936), immune system process (GO:0002376), protein ubiquitination (GO:0016567), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of viral process (GO:0048524), regulation of viral life cycle (GO:1903900)

GO Molecular Function (6): transcription coactivator activity (GO:0003713), zinc ion binding (GO:0008270), ubiquitin protein ligase activity (GO:0061630), protein binding (GO:0005515), transferase activity (GO:0016740), metal ion binding (GO:0046872)

GO Cellular Component (2): cytoplasm (GO:0005737), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Interferon Signaling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein modification by small protein conjugation	2
symbiont entry into host cell	2
regulation of viral process	2
cellular anatomical structure	2
gene expression	1
regulation of macromolecule biosynthetic process	1
peptidyl-lysine modification	1
regulation of type I interferon production	1
interferon-beta production	1
canonical NF-kappaB signal transduction	1
regulation of canonical NF-kappaB signal transduction	1
positive regulation of intracellular signal transduction	1
ubiquitin-dependent protein catabolic process	1
proteasomal protein catabolic process	1
viral genome replication	1
regulation of viral genome replication	1
positive regulation of viral process	1
immune response	1
defense response to symbiont	1
modulation by symbiont of entry into host	1
regulation of viral life cycle	1
regulation of viral entry into host cell	1
positive regulation by symbiont of entry into host	1
positive regulation of viral life cycle	1
negative regulation of response to biotic stimulus	1
negative regulation of defense response	1
negative regulation of response to external stimulus	1
regulation of defense response to virus	1
defense response to virus	1
protein polyubiquitination	1
biological_process	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
viral process	1
positive regulation of biological process	1
viral life cycle	1
transcription coregulator activity	1
positive regulation of DNA-templated transcription	1
transition metal ion binding	1

Protein interactions and networks

STRING

971 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TRIM38	TRIM56	Q9BRZ2	679
TRIM38	TAB2	Q9NYJ8	678
TRIM38	TRAT1	Q6PIZ9	625
TRIM38	CGAS	Q8N884	613
TRIM38	TRIM32	Q13049	552
TRIM38	ZCCHC3	Q9NUD5	549
TRIM38	PRY	O14603	507
TRIM38	BBOX1	O75936	479
TRIM38	TRAF6	Q9Y4K3	473
TRIM38	TRIM9	Q9C026	467
TRIM38	IRF3	Q14653	463
TRIM38	TBK1	Q9UHD2	462
TRIM38	TRIM23	P36406	460
TRIM38	USP4	Q13107	460
TRIM38	TRIM14	Q14142	447
TRIM38	RIGI	O95786	447

IntAct

106 interactions, top by confidence:

A	B	Type	Score
TRIM38	RFC5	psi-mi:“MI:0915”(physical association)	0.830
STXBP1	TRIM38	psi-mi:“MI:0915”(physical association)	0.810
TRIM38	STXBP1	psi-mi:“MI:0915”(physical association)	0.810
TRIM38	UBE2I	psi-mi:“MI:0915”(physical association)	0.720
HSPA8	TRIM38	psi-mi:“MI:0915”(physical association)	0.720
GORASP2	TRIM38	psi-mi:“MI:0915”(physical association)	0.720
TSPYL4	TRIM38	psi-mi:“MI:0915”(physical association)	0.720
UBE2I	TRIM38	psi-mi:“MI:0915”(physical association)	0.720
TRIM38	HSPA8	psi-mi:“MI:0915”(physical association)	0.720
TRIM38	GORASP2	psi-mi:“MI:0915”(physical association)	0.720
TRIM38	TSPYL4	psi-mi:“MI:0915”(physical association)	0.720
TRIM38	ATXN1	psi-mi:“MI:0915”(physical association)	0.700

BioGRID (88): TRIM38 (Two-hybrid), TRIM38 (Two-hybrid), TRIM38 (Two-hybrid), TRIM38 (Two-hybrid), TRIM38 (Two-hybrid), TRIM38 (Two-hybrid), TRIM38 (Two-hybrid), TRIM38 (Two-hybrid), TSPYL4 (Two-hybrid), GORASP2 (Two-hybrid), GMCL1 (Two-hybrid), AZI2 (Affinity Capture-Western), TRIM38 (Affinity Capture-Western), TRIM38 (Affinity Capture-MS), TRIM38 (Affinity Capture-MS)

ESM2 similar proteins: A0A0E4BZH1, A4QPC6, A7TZE6, A8K4G0, A8MVZ5, O00478, O00481, O00635, O70355, O75677, O75679, P14373, P18892, P19474, P55803, P78410, Q13410, Q1XHU0, Q3ZEE5, Q58DK8, Q5BN31, Q5C8U1, Q5D7H8, Q5D7I0, Q5D7I2, Q5D7I3, Q5D7I5, Q5D7J2, Q5R7W8, Q5R996, Q61885, Q62158, Q62191, Q62556, Q6MFZ5, Q6MG97, Q6UX41, Q6UXE8, Q6UXG8, Q7KYR7

Diamond homologs: A0JN74, A6NCK2, A6NDI0, A6NGJ6, A6NI03, A6NK02, A6NLI5, B1H278, C9J1S8, K7N6K2, O00635, O15553, O19085, O77666, P0CI25, P0CI26, P14373, P15533, P18892, P19474, Q02084, Q0PF16, Q12899, Q13410, Q1ACD5, Q1ACD6, Q1ACD7, Q1ACD8, Q1XHU0, Q2T9Z0, Q2YEM8, Q2YEM9, Q2YEN0, Q2YEN2, Q3UWZ0, Q3ZEE5, Q495X7, Q587N6, Q587N7, Q58DK8

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
Ub:E2	“up-regulates activity”	TRIM38	ubiquitination
TRIM38	“down-regulates quantity by destabilization”	TRIM38	polyubiquitination
TRIM38	“down-regulates quantity by destabilization”	TRAF6	polyubiquitination

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 32 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
PKR-mediated signaling	5	33.6×	3e-05

GO biological processes:

GO term	Partners	Fold	FDR
response to unfolded protein	5	60.2×	5e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

55 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	38
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1806 predictions. Top by Δscore:

Variant	Effect	Δscore
6:25969416:GGAAA:G	donor_gain	1.0000
6:25969417:GAAA:G	donor_gain	1.0000
6:25969417:GAAAG:G	donor_gain	1.0000
6:25969418:A:T	donor_gain	1.0000
6:25969421:G:GG	donor_gain	1.0000
6:25973161:T:TA	acceptor_gain	1.0000
6:25973166:A:AG	acceptor_gain	1.0000
6:25973168:TCTA:T	acceptor_loss	1.0000
6:25973169:CTA:C	acceptor_loss	1.0000
6:25973171:A:AG	acceptor_gain	1.0000
6:25973171:AG:A	acceptor_gain	1.0000
6:25973172:G:GA	acceptor_gain	1.0000
6:25973172:GG:G	acceptor_gain	1.0000
6:25973172:GGA:G	acceptor_gain	1.0000
6:25973172:GGAGT:G	acceptor_gain	1.0000
6:25973284:AGG:A	donor_loss	1.0000
6:25973286:G:GA	donor_loss	1.0000
6:25973286:G:GG	donor_gain	1.0000
6:25973287:T:A	donor_loss	1.0000
6:25983162:A:AG	acceptor_gain	1.0000
6:25983163:G:GA	acceptor_gain	1.0000
6:25983163:GT:G	acceptor_gain	1.0000
6:25983163:GTT:G	acceptor_gain	1.0000
6:25983163:GTTA:G	acceptor_gain	1.0000
6:25983259:G:GT	donor_gain	1.0000
6:25983323:G:GT	donor_gain	1.0000
6:25962856:G:GG	donor_gain	0.9900
6:25963279:CCCGG:C	donor_loss	0.9900
6:25963282:GGTAA:G	donor_loss	0.9900
6:25963283:G:A	donor_loss	0.9900

AlphaMissense

3078 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:25983277:T:C	F330L	0.978
6:25983279:T:A	F330L	0.978
6:25983279:T:G	F330L	0.978
6:25983364:T:A	W359R	0.976
6:25983364:T:C	W359R	0.976
6:25983598:T:C	F437L	0.973
6:25983600:C:A	F437L	0.973
6:25983600:C:G	F437L	0.973
6:25983433:T:C	F382L	0.971
6:25983435:C:A	F382L	0.971
6:25983435:C:G	F382L	0.971
6:25966829:T:C	F103L	0.966
6:25966831:C:A	F103L	0.966
6:25966831:C:G	F103L	0.966
6:25966856:T:C	C112R	0.966
6:25983374:G:A	G362E	0.961
6:25983592:T:C	F435L	0.961
6:25983594:T:A	F435L	0.961
6:25983594:T:G	F435L	0.961
6:25966568:T:C	C16R	0.959
6:25983436:T:A	W383R	0.959
6:25983436:T:C	W383R	0.959
6:25966621:C:A	H33Q	0.958
6:25966621:C:G	H33Q	0.958
6:25966622:A:C	S34R	0.958
6:25966624:C:A	S34R	0.958
6:25966624:C:G	S34R	0.958
6:25983562:T:C	F425L	0.957
6:25983564:T:A	F425L	0.957
6:25983564:T:G	F425L	0.957

dbSNP variants (sampled 300 via entrez): RS1000074104 (6:25975760 T>A,C), RS1000334942 (6:25969727 T>G), RS1000367677 (6:25995417 G>A), RS1000386608 (6:25976118 G>A), RS1000449235 (6:25969247 T>C), RS1000479702 (6:25962678 G>A), RS1000611630 (6:25969570 T>C), RS1000647290 (6:25990218 C>A), RS1000940588 (6:25967686 C>T), RS1000962943 (6:25981282 C>T), RS1001168134 (6:25982459 C>T), RS1001213053 (6:25970893 A>G), RS1001224312 (6:25963737 C>T), RS1001306575 (6:25984048 A>G), RS1001351177 (6:25991113 T>G)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

19 associations (top):

Study	Trait	p-value
GCST000301_14	Iron status biomarkers	4.000000e-06
GCST000960_14	Cardiac hypertrophy	2.000000e-07
GCST004521_113	Autism spectrum disorder or schizophrenia	3.000000e-19
GCST004521_169	Autism spectrum disorder or schizophrenia	4.000000e-14
GCST004521_69	Autism spectrum disorder or schizophrenia	8.000000e-24
GCST004521_83	Autism spectrum disorder or schizophrenia	1.000000e-13
GCST004748_55	Lung cancer	1.000000e-09
GCST004749_111	Lung cancer in ever smokers	6.000000e-08
GCST008163_121	Height	7.000000e-06
GCST010002_50	Refractive error	4.000000e-34
GCST010142_16	Fish- and plant-related diet	2.000000e-10
GCST010142_19	Fish- and plant-related diet	4.000000e-10
GCST010142_34	Fish- and plant-related diet	7.000000e-09
GCST010142_35	Fish- and plant-related diet	8.000000e-09
GCST010142_42	Fish- and plant-related diet	1.000000e-08
GCST010142_7	Fish- and plant-related diet	3.000000e-12
GCST010702_75	Subcortical volume (MOSTest)	3.000000e-11
GCST010703_272	Brain morphology (MOSTest)	7.000000e-16
GCST012231_233	A body shape index	9.000000e-11

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004461	iron biomarker measurement
EFO:0002503	cardiac hypertrophy
EFO:0008111	diet measurement
EFO:0004346	neuroimaging measurement
EFO:0007789	BMI-adjusted waist circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — 2.3.2.27 RING-type E3 ubiquitin transferase

CTD chemical–gene interactions

59 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	5
Aflatoxin B1	affects expression, increases expression	4
trichostatin A	increases expression, affects cotreatment	3
sodium arsenite	affects methylation, increases expression	3
Cisplatin	decreases expression, increases expression	3
Tretinoin	increases expression	3
nickel sulfate	decreases expression, increases expression	2
mercuric bromide	increases expression, affects cotreatment	2
Panobinostat	affects cotreatment, increases expression	2
Acetaminophen	decreases expression, increases expression	2
Benzo(a)pyrene	increases expression	2
Calcitriol	increases expression, affects cotreatment	2
Ethyl Methanesulfonate	decreases expression, increases expression	2
Phenylmercuric Acetate	increases expression, affects cotreatment	2
Testosterone	decreases expression, affects cotreatment, increases expression	2
TAK-243	increases sumoylation	1
testosterone enanthate	affects expression	1
bisphenol A	decreases methylation	1
glycidyl methacrylate	decreases expression	1
titanium dioxide	increases methylation	1
2-butenal	decreases expression	1
arsenite	affects binding, decreases reaction	1
butyraldehyde	decreases expression	1
zinc chromate	increases abundance, increases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	increases abundance, increases expression	1
perfluoro-n-nonanoic acid	increases expression	1
2-palmitoylglycerol	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1ID	Abcam A-549 TRIM38 KO 1	Cancer cell line	Male
CVCL_B2QX	Abcam A-549 TRIM38 KO 2	Cancer cell line	Male
CVCL_TU17	HAP1 TRIM38 (-) 1	Cancer cell line	Male
CVCL_TU18	HAP1 TRIM38 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.